Lilly Asia Ventures

A biomedical venture capital firm investing in biopharmaceuticals, medical technologies, and diagnostics.

Venture Capital Active Shanghai, China Est. 2008
Last updated 2026-07-20
Portfolio
1
in our dataset
Rounds participated
1
Rounds led
1
Rounds' value
$110.0M
total disclosed, rounds participated
Stages
—

About

Lilly Asia Ventures (LAV) is a biomedical venture capital firm that originated in 2008 as a corporate venture subsidiary of Eli Lilly and spun off as an independent investment management company in 2011. With offices in Shanghai, Hong Kong, and Palo Alto, LAV invests globally across the full biomedical spectrum, from seed stage to publicly traded companies. They focus on biopharmaceuticals, human therapeutics, medical devices, and diagnostics. LAV manages approximately $4.5 billion in assets across seven funds. The firm aims to be a trusted partner for entrepreneurs, providing deep scientific networks across Asia and North America, clinical development expertise, regulatory knowledge, and global licensing relationships.

Portfolio · 1

RiboX Therapeutics
Developer of fully engineered circular RNA therapeutics for various diseases.
Led ★ 1 round $110.0M committed Latest: 2022-07

Investment activity

Portfolio by sector

Health Tech & Life Sciences1

Q&A

What is Lilly Asia Ventures' most recent investment?
Lilly Asia Ventures participated in Nucleix's Series C round in April 2021, which raised $88.3M.
Which sectors does Lilly Asia Ventures primarily invest in?
Lilly Asia Ventures has invested in the Health Tech & Life Sciences sector, with one portfolio company in this area.
What is the typical investment stage for Lilly Asia Ventures?
Lilly Asia Ventures has participated in a Series C round, as seen with their investment in Nucleix.
Can you name a notable portfolio company of Lilly Asia Ventures?
Nucleix, a company focused on noninvasive testing for early detection of cancer, is a portfolio company of Lilly Asia Ventures.
When was Lilly Asia Ventures' last recorded investment activity?
Lilly Asia Ventures' last recorded investment activity was in April 2021.
What is the investment range for Lilly Asia Ventures?
Lilly Asia Ventures has an investment range of $55M - $55M.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2008